0547427 - FGÚ 2022 RIV FR eng J - Journal Article
Hojná, Silvie - Rauchová, Hana - Malínská, H. - Marková, I. - Hüttl, M. - Papoušek, František - Behuliak, Michal - Miklánková, D. - Vaňourková, Z. - Neckář, Jan - Kadlecová, Michaela - Kujal, P. - Zicha, Josef - Vaněčková, Ivana
Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension.
Biomedicine & Pharmacotherapy. Roč. 144, Dec (2021), č. článku 112246. ISSN 0753-3322. E-ISSN 1950-6007
R&D Projects: GA ČR(CZ) GA19-06199S
Institutional support: RVO:67985823
Keywords : SGLT-2 inhibitor * cardiac * renal and metabolic parameters
OECD category: Physiology (including cytology)
Impact factor: 7.419, year: 2021
Method of publishing: Open access
https://doi.org/10.1016/j.biopha.2021.112246
Permanent Link: http://hdl.handle.net/11104/0323665
Hojná, Silvie - Rauchová, Hana - Malínská, H. - Marková, I. - Hüttl, M. - Papoušek, František - Behuliak, Michal - Miklánková, D. - Vaňourková, Z. - Neckář, Jan - Kadlecová, Michaela - Kujal, P. - Zicha, Josef - Vaněčková, Ivana
Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension.
Biomedicine & Pharmacotherapy. Roč. 144, Dec (2021), č. článku 112246. ISSN 0753-3322. E-ISSN 1950-6007
R&D Projects: GA ČR(CZ) GA19-06199S
Institutional support: RVO:67985823
Keywords : SGLT-2 inhibitor * cardiac * renal and metabolic parameters
OECD category: Physiology (including cytology)
Impact factor: 7.419, year: 2021
Method of publishing: Open access
https://doi.org/10.1016/j.biopha.2021.112246
Permanent Link: http://hdl.handle.net/11104/0323665